Patent ID: 7300763
Filing Date: 2007-11-27
Classification: G01N,Y10T

Abstract:
1. A method for evaluating the myelotoxicity of a drug hematopoiesis in bone marrow, said method comprising: administering the drug to an animal, and measuring the number of bone marrow-derived cells that express at least one of CD45, CD45R, CD71, or CD90 by flow cytometrically analyzing CD45, CD45R, CD71, or CD90 cell surface antigen expression by the bone marrow-derived cells; and providing an indication that the drug has myelotoxicity to hematopoiesis in bone marrow when a decrease in the number of CD45, CD45R, CD71, or CD90 expressing cells, either over time or in relation to cells from untreated animals, is measured based on flow cytometric analysis of CD45 peak1, CD45R, CD71, or CD90.